Research · Sep 3, 2026
[AXTI] AXT Inc Thesis 2026: An Indium-Phosphide Specialist Rides AI-Optical and Tongmei IPO Optionality
AXT Inc (NASDAQ: AXTI), headquartered in Fremont, California (with ~95%+ of manufacturing operations in Beijing + Tianjin + other China-facilities), is a specialty compound-semiconductor-substrate supplier producing Indium-Phosphide (InP) + Gallium-Arsenide (GaAs) + Germanium (Ge) compound-semiconductor-substrates for 5G/6G RF + AI-data-center optical-fiber + datacom/telecom + photonic + VCSEL + LED + solar + space + IR-detector + other compound-semi applications globally. Founded in 1986 by Morris Young + co-founders in Fremont, California with selectively-distinctive multi-decade founder-led-and-controlled history, IPO'd 1998 on NASDAQ, and has operated continuously for ~40 years. Through multi-decade strategic-evolution AXT built vertically-integrated China-manufacturing-and-raw-material operations (Beijing + Tianjin + Tongmei subsidiary), three-substrate-product-line franchise (InP + GaAs + Ge), strategic-pivot toward InP-AI-optical growth segment, Tongmei IPO Beijing-Stock-Exchange filing pursuit since 2021-2022, and multi-cycle navigation of US-China-trade-and-export-controls environment. Under President & CEO Morris Young (CEO since founding 1986, co-founder + longtime CEO with family-control + selectively-distinctive multi-decade founder-led-and-controlled compound-semi pure-play), FY2025 closes with selected various aggregate revenue ~$0.10-0.12B (~10-25% YoY recovery), gross margin ~25-30%, operating margin slightly-positive to negative, EPS ~$(0.10) to $+0.30, and ~46M shares outstanding. The first deep-dive — Indium-Phosphide + Gallium-Arsenide + Germanium compound-semi-substrate franchise — covers the three-substrate-product-line specialty-manufacturer. Indium Phosphide (InP) substrates (~30-40% revenue, ~$30-40M) is the strategic-growth-segment + most-valuable product-line enabling AI-data-center optical-transceivers (800G + 1.6T + 3.2T + Silicon-Photonics-integrated optical-modules + co-packaged-optics), 5G/6G RF + PA front-end-modules + cellular + WiFi, VCSEL (Vertical-Cavity Surface-Emitting Lasers for 3D-sensing including Apple iPhone Face-ID + AR/VR + datacom), and lasers (edge-emitting for datacom). AXT is selectively-one-of-three-dominant-global-InP-substrate-suppliers alongside Sumitomo Electric Industries (5802-JP dominant Japanese with largest InP-substrate market-share) and InfraGreen/NEM-Tek/other Japanese-Chinese-and-European alternatives. Gallium Arsenide (GaAs) substrates (~30-40%, ~$30-40M) is mature segment for RF/microwave PA + LED + other compound-semi competing with Sumitomo Electric, Freiberger Compound Materials (private German), DOWA Electronics (5713-JP). Germanium (Ge) substrates (~15-20%, ~$15-20M) for solar (multi-junction-photovoltaic for space + concentrator) + space + IR-detector, selectively-positioned for space-and-defense satellite-photovoltaic demand growth. Raw Materials sub-companies (~10-15%, ~$10-15M) vertically-integrated via Tongmei + other producing gallium + germanium + indium + arsenic feedstock for internal-production + third-party-merchant-sales. FY2026 catalyst is AI-optical InP demand acceleration + VCSEL growth + utilization-improvement + 6-inch InP capacity-ramp. Competes with Sumitomo Electric (5802-JP), Yunnan Germanium (002428-CN), Umicore (UMI-BE), JX Nippon Mining (5020-JP), Win Semiconductors (3105-TW dominant GaAs-foundry), Freiberger Compound Materials, DOWA Electronics; downstream customers Lumentum (LITE), Coherent (COHR), MACOM (MTSI), Marvell (MRVL), Skyworks (SWKS), Qorvo (QRVO), Broadcom (AVGO), Cisco (CSCO), Ciena (CIEN), Innolight (300308-CN), Eoptolink (300502-CN), HG Genuine (002281-CN). The second deep-dive — Tongmei IPO optionality + vertical-integration + US-China-trade-and-export-controls + multi-decade compounder thesis — covers vertical-integration via ~95%+ China-operations (low-cost-manufacturing-base + vertical-integration with raw-material-subsidiaries + direct-China-customer-relationships) and selective US-China-trade exposure (Section 301 tariffs + Section 1260H CMC-list-designation-risk + 2023-2024 China-implemented gallium-and-germanium-export-restrictions + US-implemented compound-semi-export-controls + US-China-decoupling-risk). Tongmei IPO: AXT's primary China-raw-materials-and-substrate subsidiary filed for IPO on Beijing Stock Exchange + IPO under-review-and-pending CSRC-approval through multi-year filing-cycle since 2021-2022 (selectively-elevated-execution-uncertainty but substantial-potential-value-unlock if executed — selectively-Tongmei-IPO at $1-2B+ market-cap could unlock substantial-value vs current ~$80-120M AXT-consolidated market-cap). Multi-decade compounder thesis combines Indium-Phosphide AI-optical structural-tailwind (AI-data-center growth + 800G→1.6T→3.2T optical roadmap = multi-decade InP-demand), compound-semi-substrate-niche-specialist-position (one-of-three-dominant-InP-suppliers globally), Tongmei IPO optionality, Morris Young founder-CEO continuity + family-control alignment, selective-recovery-from-trough, and vertical-integration cost-advantage. Capital position is moderately-leveraged, no-dividend, recovery-focused: net debt ~$25-50M (selectively-modest), non-rated speculative-grade-equivalent, ~$30-50M cash + undrawn revolver liquidity, FCF selectively-negative-to-modestly-positive through-trough (pressured by trough-EBITDA + working-capital + 6-inch-InP-capacity-expansion capex), no regular dividend, minimal buybacks, ~46M Class A common (broadly stable). AXT owns ~85-90%+ of Tongmei with employees/strategic-investors holding ~10-15% minority. At ~$2.0-3.5 per share, equity value ~$90-160M, EV ~$115-210M, ~1.0-2.0x revenue and ~12-25x EV/EBITDA. Base case: revenue grows ~15-25% + gross margin ~28-32% + EPS slightly-positive $0.05-0.35 + Tongmei IPO progresses + ~10-25% return. Bull case: AI-optical accelerates + revenue grows ~30-45% + gross margin ~32-37% + EPS $0.30-0.70 + Tongmei IPO executes + re-rate 2.5-4.0x revenue + 50-100%+ return. Bear case: US-China-trade intensifies + operations impaired + Tongmei indefinitely-stalled + de-rate 0.7-1.0x revenue + flat-to-negative + distress-risk.